Sarepta provides safety update for elevidys and initiates steps to strengthen safety in non-ambulatory individuals with duchenne

Cambridge, mass.--(business wire)--sarepta therapeutics, inc. (nasdaq:srpt), the leader in precision genetic medicine for rare diseases, today provided a safety update regarding elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy for patients with duchenne muscular dystrophy, and steps the company is taking to strengthen the safety profile in non-ambulatory patients. these steps follow a second reported case of acute liver failure (alf) resulting in death. the cases of.
SRPT Ratings Summary
SRPT Quant Ranking